Greenwich LifeSciences In... (GLSI)
8.98
-0.45 (-4.77%)
At close: Apr 10, 2025, 12:34 PM
-4.77% (1D)
| Bid | 8.8 |
| Market Cap | 118.04M |
| Revenue (ttm) | 5.42K |
| Net Income (ttm) | -10.5M |
| EPS (ttm) | -0.81 |
| PE Ratio (ttm) | -11.09 |
| Forward PE | -16.01 |
| Analyst | Buy |
| Ask | 9.2 |
| Volume | 36,479 |
| Avg. Volume (20D) | 60,229 |
| Open | 9.46 |
| Previous Close | 9.43 |
| Day's Range | 8.80 - 9.60 |
| 52-Week Range | 8.06 - 18.75 |
| Beta | 3.38 |
About GLSI
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company was formerly known as Norwell, Inc. and changed its name t...
Industry Biotechnology
Sector Healthcare
IPO Date Sep 25, 2020
Employees 3
Stock Exchange NASDAQ
Ticker Symbol GLSI
Analyst Forecast
According to 1 analyst ratings, the average rating for GLSI stock is "Buy." The 12-month stock price forecast is $38, which is an increase of 323.16% from the latest price.
Stock Forecasts1 week ago
+0.97%
Greenwich LifeSciences shares are trading higher a...
Unlock content with
Pro Subscription
